TY - JOUR
T1 - Retrospective analysis of treatment outcome of pediatric ependymomas in Korea
T2 - Analysis of Korean multi-institutional data
AU - Kim, Yeon Joo
AU - Kim, Joo Young
AU - Lim, Do Hoon
AU - Park, Hyeon Jin
AU - Joo, Jungnam
AU - Sung, Ki Woong
AU - Shin, Hyung Jin
AU - Kim, Seung Ki
AU - Phi, Ji Hoon
AU - Kim, Il Han
AU - Park, Kyung Duk
AU - Ahn, Seung Do
AU - Jung, Jinhong
AU - Rha, Young Sin
AU - Kim, Dong Seok
AU - Suh, Chang Ok
N1 - Funding Information:
Acknowledgments National Cancer Center, Korea (Grant No. 1010480); National Research and Development Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (No. 0520300).
PY - 2013/5
Y1 - 2013/5
N2 - We analyzed the treatment outcomes of intracranial ependymomas in Korean children aged <18 years. Data for 96 patients were collected from five hospitals. Survival rates were calculated using the Kaplan-Meier method. Log-rank tests for univariate analyses and Cox regression model for multivariate analysis were conducted to identify prognostic factors for survival. The median age of the patients was 4 years (range, 0.3-17.9 years). The median follow-up was 55 months (range, 2-343 months). Age <3 years was an important factor for selecting adjuvant therapy after surgery. Among children aged <3 and ≥3 years, adjuvant radiotherapy (RT) was applied to 55 and 84 %, respectively, and adjuvant chemotherapy to 52 and 10 %, respectively. The 5 year local progression-free survival (LPFS), disease-free survival (DFS), and overall survival (OS) rates were 54, 52, and 79 %, respectively. Gross total resection was the most significant prognostic factor for all survival endpoints. Age ≥3 years and RT were significant prognostic factors for superior LPFS and DFS. However, the significance of age was lost in multivariate analysis for DFS. LPFS, DFS, and OS were superior in patients who started RT within 44 days after surgery (the median time) than in patients who started RT later in the patients aged ≥3 years. Postoperative RT was a strong prognostic factor for intracranial ependymomas. Our results suggest that early use of RT is an essential component of treatment, and should be considered in young children.
AB - We analyzed the treatment outcomes of intracranial ependymomas in Korean children aged <18 years. Data for 96 patients were collected from five hospitals. Survival rates were calculated using the Kaplan-Meier method. Log-rank tests for univariate analyses and Cox regression model for multivariate analysis were conducted to identify prognostic factors for survival. The median age of the patients was 4 years (range, 0.3-17.9 years). The median follow-up was 55 months (range, 2-343 months). Age <3 years was an important factor for selecting adjuvant therapy after surgery. Among children aged <3 and ≥3 years, adjuvant radiotherapy (RT) was applied to 55 and 84 %, respectively, and adjuvant chemotherapy to 52 and 10 %, respectively. The 5 year local progression-free survival (LPFS), disease-free survival (DFS), and overall survival (OS) rates were 54, 52, and 79 %, respectively. Gross total resection was the most significant prognostic factor for all survival endpoints. Age ≥3 years and RT were significant prognostic factors for superior LPFS and DFS. However, the significance of age was lost in multivariate analysis for DFS. LPFS, DFS, and OS were superior in patients who started RT within 44 days after surgery (the median time) than in patients who started RT later in the patients aged ≥3 years. Postoperative RT was a strong prognostic factor for intracranial ependymomas. Our results suggest that early use of RT is an essential component of treatment, and should be considered in young children.
UR - http://www.scopus.com/inward/record.url?scp=84876919272&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876919272&partnerID=8YFLogxK
U2 - 10.1007/s11060-013-1087-5
DO - 10.1007/s11060-013-1087-5
M3 - Article
C2 - 23462854
AN - SCOPUS:84876919272
SN - 0167-594X
VL - 113
SP - 39
EP - 48
JO - Journal of Neuro-Oncology
JF - Journal of Neuro-Oncology
IS - 1
ER -